Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma

Bone Marrow Transplantation (2024)Cite this article

Subjects

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATL), but outcomes are still unsatisfactory [1, 2]. The first choice of donors for allo-HCT of ATL are HLA-matched relatives, but sibling donors are difficult to find because ATL is common in elderly individuals [3]. The next candidate, an HLA-matched unrelated donor, takes time to coordinate and can be difficult to transplant at the appropriate time [4]. Therefore, cord blood (CB) is a candidate alternative donor source, but the 1-year OS was only 38% in Japan [5].

Recently, Tanaka et al. conducted a multicenter single-arm trial of HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide (PTCy-Haplo PBSCT) for aggressive ATL, which showed a good 2-year OS of 73% with a median follow-up of 572 days [6]. To our knowledge, only one study has compared HLA-haploidentical allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide (PTCy-Haplo HCT) with others, with a median follow-up of 728 days [7]. To date, there have been no reports on the long-term comparison of PTCy-Haplo HCT with transplantation using other donor types.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Transplant outcomes stratified by different donor type.

Data availability

The dataset analyzed in this study is available from the corresponding author upon reasonable request.

References

  1. Bazarbachi A-H, Reef D, Narvel H, Patel R, Al Hamed R, Vikash S, et al. Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. Clin Hematol Int. 2023;5:78–91.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Utsunomiya A. Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2019;10:2235.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, et al. Epidemiological and clinical features of adult T-cell leukemia–lymphoma in Japan, 2010–2011: A nationwide survey. Cancer Sci. 2017;108:2478–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transpl. 2016;51:205–11.

    Article  CAS  Google Scholar 

  5. Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, et al. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. Bone Marrow Transpl. 2021;56:155–66.

    Article  CAS  Google Scholar 

  6. Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, et al. A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. Transplant Cell Ther. 2021;27:928.e1–e7.

    Article  CAS  PubMed  Google Scholar 

  7. Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5:4156–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76.

    Article  CAS  PubMed  Google Scholar 

  9. Ishii K, Okamoto S, Fujita M, Sugihara A, Nagaie T, Nishioka A, et al. [HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide for adult T-cell leukemia]. Rinsho Ketsueki. 2022;63:333–40.

    PubMed  Google Scholar 

  10. Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, et al. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma. Bone Marrow Transpl. 2019;54:1266–74.

    Article  CAS  Google Scholar 

  11. Bashey A, Zhang M-J, McCurdy SR, Martin AS, Argall T, Anasetti C, et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017;35:3002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. JCO. 2016;34:3426–33.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the Japan Society for the Promotion of Science (JSPS; KAKENHI Grant number 23K06746) and the Project Mirai Cancer Research Grants.

Author information

Authors and Affiliations

  1. Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

    Asao Hirose, Hideo Koh, Mika Nakamae, Yasuhiro Nakashima, Mitsutaka Nishimoto, Hiroshi Okamura, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Kentaro Ido, Kazuki Sakatoku, Masayuki Hino & Hirohisa Nakamae

  2. Department of Preventive Medicine and Environmental Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

    Hideo Koh

  3. Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

    Mika Nakamae, Hiroshi Okamura, Kentaro Ido & Masayuki Hino

Authors
  1. Asao Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideo Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mika Nakamae
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhiro Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsutaka Nishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yosuke Makuuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masatomo Kuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Teruhito Takakuwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kentaro Ido
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazuki Sakatoku
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Masayuki Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hirohisa Nakamae
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AH, HK, and HN contributed to the conceptualization and design of the study. AH and MNa collected and cleaned data. AH, HK, KI analyzed the data, and AH, HK, and HN interpreted the results and wrote the draft. MNa, YN, MNi, HO, YM, MK, TT, KS, KI, and MH interpreted the results, and critically reviewed and revised the manuscript. All authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Hirohisa Nakamae.

Ethics declarations

Competing interests

The potential conflicts of interest for each author are as follows: HK received honoraria from Novartis. MNa’s spouse received honoraria (HN’s interests). YN received research funding from Astellas, Chugai, Novartis, and honoraria from Astellas, Kyowa Kirin, and Chugai. MNi received research funding from Astellas and Pfizer, and honoraria from Nippon Shinyaku, Otsuka, and Takeda. HO received research funding from Takeda, and honoraria from Nippon Shinyaku. TT received research funding from Pfizer, and honoraria from Chugai, Kyowa Kirin, Novartis, Takeda, and Sanofi. MH received research funding from Nippon Shinyaku; scholarship grants from Chugai, JCR Pharmaceuticals, Kyowa Kirin, Takeda, and Otsuka; and honoraria from Astellas, Chugai, Kyowa Kirin, Nippon Shinyaku, Novartis, Otsuka, Pfizer, Sanofi, and Takeda. HN received research funding from Astellas, Novartis, and Takeda, and honoraria from Astellas, Chugai, Nippon Shinyaku, Novartis, Otsuka, and Takeda. This study was not funded by any of these companies. The other authors declare no conflicts of interest associated with this manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hirose, A., Koh, H., Nakamae, M. et al. A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02231-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-024-02231-4

Search

Advanced search

Quick links